We previously reported that intrathecal pro-opiomelanocortin gene electroporation could reduce pain sensitivity induced by chronic constriction injury (CCI) of the sciatic nerve. For optimal use of antinociceptive gene therapy, it might be important to control the expression of the transfected gene extrinsically. For this purpose, a doxycyclinecontrolled transrepressor system composed of two plasmids coding, respectively, for pro-opiomelanocortin gene (pTRE2-POMC) and the silencer (pTel-off) was employed. The regulation of beta-endorphin expression was first assessed in spinal neuronal culture, then we electrotranfected this plasmid into the spinal cord of mononeuropathic rats and evaluated the analgesic potential of this therapy in vivo by thermal and mechanical withdrawal latency. Intraperitoneal injections of various doses of doxycycline were made to elucidate the possible exogenous downregulation of transfected beta-endorphin gene expression in vivo. The levels of beta-endorphin were analyzed by intrathecal microdialysis and radioimmunoassay. Intrathecal pTRE2-POMC/pTel-off electroporation elevated spinal betaendorphin levels, as manifested in a significantly elevated pain threshold for chronic constriction injury limbs. Intraperitoneal doxycycline decreased the antinociceptive effect and spinal beta-endorphin levels in a dose-dependent manner. We concluded that intrathecal pTRE2-POMC/ pTel-off electroporation alleviates CCI-induced limb pain, and can be controlled by intraperitoneal doxycycline administration.
Introduction
Beta-endorphin, when administered intrathecally, can produce profound and long-lasting analgesia in patients with intractable pain. 1, 2 It has long been known to be a strong antinociceptive agent for thermal and nonthermal stimuli, 3 and is considered 21 times more potent an opiate than morphine. 4 This spinal antinociceptive effect is believed to be mediated through opioid binding that takes place in the spinal dorsal horn, at sites pre-and postsynaptic to the primary afferent terminal. [5] [6] [7] At these sites, the opioid agonists act to block afferent excitatorytransmitter release, [8] [9] [10] and depress the excitability of second-order neurons. 3, 11 Several studies revealed that continuous infusion of opiate is more effective than bolus injection for long-term pain control. [12] [13] [14] It has been proven that long-term administration of low doses of opiate to the patient's spinal cord caused analgesia without the development of tolerance or the side effects that occur with activation of brain opiate receptors. 14, 15 Therefore, infusion pump, cell transplantation or viral vector deliveries for continuous delivery of opioid agonists into the subarachnoid space have been developed for the treatment of pain. 16 However, these methods have certain disadvantages and side effects. 17, 18 In previous studies, 17, 19 we have shown that it is possible to achieve effective gene expression using spinal electroporation combined with intrathecal plasmid delivery, particularly for meningeal and pia mater cells, and for those localized in the superficial layers. Intrathecal electroporation of the pro-opiomelanocortin (POMC) vector elevated spinal beta-endorphin levels, as manifested in a significantly elevated pain threshold for chronic constriction injury (CCI) of the limbs.
Clinically, however, the (re)introduction of a gene function into a patient would only be acceptable if the activity of that gene can be maintained within a welldefined therapeutic window, thereby preventing toxicity while adapting gene expression to varying physiological parameters. 20 Toward this goal, several transcription regulatory systems have been devised that allow gene expression to be controlled through a small inducer molecule. 21 For gene therapy, such systems have to fulfill several prerequisites. Not only must the inducer molecule be acceptable in clinical practice, but the transcription rate of the gene must also be dependent on the inducer dose. Furthermore, regulation has to be tight, and the regulatory window must be wide. 22 The tetracycline (Tc)-dependent regulatory system (Tet system) has progressively improved to meet these requirements. 23 The tetracycline-controllable expression system offers a number of advantages: strict on/off regulation, high inducibility, short response times, specificity, no interference with the cellular pathway, bioavailability of a nontoxic inducer, and dose dependence.
The Tet-off system, 24 which uses the tetracyclineresponsive transcriptional activator (tTA), and the Tet-on system, 25 which uses the reverse tetracyclineresponsive transcriptional activator (rtTA), provide negative and positive control of transgene expression, respectively. A number of reports have demonstrated that the tTA system facilitates doxycycline-dependent regulation of gene expression in animal models of gene therapy. 26 In this study, we have used a doxycycline-controlled transrepressor system to demonstrate that beta-endorphin production can be controlled in a dose-responsive and reversible manner in vitro. We then transferred these constructs into the spinal cord by intrathecal electroporation and observed the regulatory effects of doxycycline on CCI-induced nociceptive behavior in rats. The approach offers a safe and simple method for regulating therapeutic protein levels of cerebrospinal fluid (CSF) in spinal cord-targeted gene therapy.
Results
Regulation of beta-endorphin secretion by doxycycline in cultured spinal neuronal cells
The potential for regulated beta-endorphin secretion by doxycycline administration was evaluated in spinal neuronal cells in vitro. Following cotransfection with pTRE2-POMC and pTet-off in the absence of doxycycline, peak total beta-endorphin secretion was 1573 pmol/l/24 h (Figure 1a) . Over the first 24-h doxycycline-free period post-transfection, there was no significant difference between groups in the amounts of beta-endorphin (ANOVA, P ¼ 0.96). Addition of 0.01, 0.1, and 1.0 mg/ml doxycycline to medium and incubation for a further 24 h (24-48 h, post-transfection) significantly reduced levels of total beta-endorphin secretion to 51, 40, and 22% of untreated cells (100%), respectively (Po0.05). This was further reduced by an additional 24 h doxycycline incubation (48-72 h, post-transfection) to 42, 8, and 5% of control in 0.01, 0.1, and 1.0 mg/ml doxycycline, respectively (Po0.05). Incubation at 0.001 mg/ml doxycycline reduced beta-endorphin secretion in comparison to untreated cells (90% at 24 h and 92% at 48 h), although decrements were not statistically significant.
To assess reversal of doxycycline inhibition, doxycycline was added to and then removed from transfected cells. Medium was collected every 24 h and analyzed for secreted beta-endorphin. Primary spinal neuronal cells were transfected with pTRE2-POMC/pTet-off. Transfected wells were separated, 48 h after transfection, into three groups: doxycycline untreated, continually treated with doxycycline (1.0 mg/ml) or 24-h doxycycline (1.0 mg/ml) treated for 1 day, with subsequent removal. Continuous addition of 1 mg/ml doxycycline to pTRE-POMC/pTet-off transfected cells reduced beta-endorphin secreted to 23, 2, and o1% over 72-96, 96-120, and 120-144 h, respectively, in comparison with untreated cells. In the doxycycline-withdrawal group, beta-endorphin secretion increased to 22% (Po0.05) and 85% (P40.05) over 96-120 and 120-144 h, respectively, in comparison with untreated cells.
Effects of pTRE2-POMC/pTel-off electroporation on general behavior
We observed the effects of intrathecal electroporation of saline alone and of pTRE2-POMC/pTel-off on the general behavior of animals (n ¼ 6 rats in all cases). All of the animals that received intrathecal electroporation under isoflurane anesthesia survived for as long as those that did not receive electric shocks. The animals showed minor lower extremity twitches while receiving the electric pulses, but these ceased as soon as the pulses ceased. No significant relationships were as is food intake, and body weights between animals treated or untreated with electric shocks. In a separate set of 30 animals divided into five groups of six, the effect of pTRE2-POMC/pTel-off antibody electroporation on CCI-induced nociceptive behavior was examined. Two groups received injections of pTRE2-POMC/pTel-off or pTRE2-POMC, followed by electroporation, while another two received injections of vehicle followed by electroporation or pTRE2-POMC/ pTel-off without electroporation. A fifth control group received injections of vehicle alone. There were no significant differences in the contralateral sham-operated paw withdrawal latencies (non-CCI side) among these five groups ( Figure 2a ). Induction of CCI resulted in an immediate decrease in the mean percentage withdrawal latency (ie, hyperalgesic state). Comparison of latency values obtained after treatment with either pTRE2-POMC or vehicle revealed no significant differences ( Figure 2b ). However, when compared with values obtained after treatment with pTRE2-POMC/ pTel-off electroporation, significantly longer withdrawal latencies were observed from day 2 through day 10 for pTRE2-POMC/pTel-off electroporation-treated animals ( Figure 2b ).
Effects of pTRE2-POMC/pTel-off electroporation on CCI-induced allodynic behavior
Among these five groups, no alteration to mechanical allodynia was demonstrated for the contralateral shamoperated limb (Figure 3a) . By contrast, mechanicalwithdrawal latency was significantly increased for CCI rats from 2 to 14 days after lesion, in comparison with intrathecal pTRE2-POMC/pTRE-off electroporation and vehicle rats (Figure 3b ).
Effects of noloxone injection on the pTRE2-POMC/ pTel-off electroporation established antinociception for CCI rats
Intraperitoneal injection of 1 mg/kg naloxone 6 days after CCI lesion did not affect either the thermal or mechanical withdrawal latencies in the vehicle animals. However, it reduced the prolonged thermal ( Figure 4a ) and mechanical latencies ( Figure 4b ) to the pre-injection value 30 min after injection in CCI rats receiving pTRE2-POMC/Tel-off electroporation. 
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Effects of doxycycline injection on the pTRE2-POMC/ pTel-off electroporation established antinociception for CCI rats
In a separate set of 30 animals divided into five groups of six, the effects of doxycycline on p-TRE2-POMC/pTeloff electroporation established antinociception were examined. Doxycycline of various doses (saline, 0.01, 0.1, and 1 mg/kg) were given (intraperitoneal) 6 days after pTRE2-POMC/pTel-off electroporation in CCI rats. A fifth group that received injections of saline electroporation served as a second control. There were no significant differences in the contralateral sham-operated paw withdrawal latencies (non-CCI side) among these five groups (data not shown). CCI rats receiving pTRE2-POMC/pTel-off electroporation showed an increase in the mean percentage withdrawal latency compared to CCI rats receiving saline electroporation. In pTRE2-POMC/pTel-off rats, comparison of latency values obtained after injection with 0.01 mg/kg doxycycline or saline revealed no significant differences (Figure 5a and b). However, when compared with values obtained after treatment with 1 mg/kg doxycycline, significantly decreased withdrawal latencies were observed from 12 through 36 h (thermal latency, Figure 5a ) or 12 through 72 h (mechanical latency, Figure 5b ) after injection. In rats receiving 0.1 mg/kg doxycycline injection, decreased thermal latency was noted at 12 h after injection (Figure 5a ).
Time course of CSF beta-endorphin levels in the lumbar spinal cord of CCI rats receiving pTRE2-POMC/pTel-off electroporation
The mean CSF beta-endorphin level based on microdialysis and radioimmunoassay (RIA) was less than 5 pmol/l in CCI rats, CCI rats receiving vehicle electroporation, and CCI rats receiving pTRE2-POMC electroporation (data not shown). The mean CSF betaendorphin level of CCI rats receiving pTRE2-POMC/ Figure 4 The effect of naloxone on thermal-and mechanical-withdrawal latency in animals that received intrathecal pTRE-POMC/pTel-off plasmid or vehicle with electroporation. Intraperitoneal injection of naloxone (3 mg/kg) 6 days after CCI lesion did not affect the latencies in the control animals but reduced the prolonged thermal latencies (a) or mechanical latency (b) values in animals that received intrathecal pTRE-POMC/pTeloff electroporation. Values are expressed as means7s.e.m. *indicates statistically significant difference from control (Po0.05). þ indicates statistically significant difference from preinjection value within group. Figure 5 The effect of doxycycline on thermal-and mechanical-withdrawal latency in the animals that received intrathecal pTRE-POMC/ptel-off plasmid with electroporation. Intraperitoneal injection of doxycycline at various doses (0-1 mg/kg) 6 days after CCI lesion did not affect the latencies in the control animals, but reduced the prolonged thermal latencies (a) or mechanical latency (b) in animals that received intrathecal pTRE-POMC/pTel-off electroporation. Values are expressed as means7 s.e.m. *indicates statistically significant difference from pTRE-POMC/ pTel-off electroporated rats receiving vehicle injection (group 0 mg/kg) (Po0.05).
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There was an increase in the beta-endorphin level from day 2 through day 14 in CCI rats receiving pTRE2-POMC/pTel-off electroporation, peaking between days 4 and 6.
Decrease in the level of CSF beta-endorphin level in pTRE2-POMC/pTel-off electroporated rats receiving intraperitoneal doxycycline
Given the proposed effects of doxycycline treatment on beta-endorphin decrement in CCI rats receiving pTRE2-POMC/pTel-off electroporation, we analyzed the abundance of CSF beta-endorphin in the lumbar spinal cords of pTRE2-POMC/pTel-off-electroporated rats receiving various doses of doxycycline (0-0.1 mg/kg). by microdialysis. Similar CSF beta-endorphin levels were seen in pTRE2-POMC/pTel-off-electrorated-CCI rats receiving vehicle or 0.01 mg/kg doxycycline injection within 60 h after injection, whereas CSF beta-endorphin levels decreased (71%, compared with vehicle rats, Po0.05) in pTRE2-POMC/pTel-off-electrorated-CCI rats receiving 0.1 mg/kg doxycycline at 12 h after injection. In pTRE2-POMC/pTel-off-electroporated-rats receiving 1 mg/kg doxycycline treatment, the CSF beta-endorphin level decreased to 12% at 12 h (Po0.05), 14% at 24 h (Po0.05), 62% (Po0.05) at 36 h, and 81% at 60 h (P40.05) (Figure 6b ).
Discussion
In this report, we used a method to transfect DNA into the spinal cord by means of electroporation with naked DNA and a microdialysis-catheter-electrode. A key aspect of targeting transfection to the spinal cord is the ability to insert the catheter-electrode into the intrathecal space of the spinal cord. Coupled with the use of a microdialysis probe, it is possible to measure the relative proteins levels over time as they participate in modifying the signal transduction of pain processing in the dorsal horn. Also, we used the plasmid encoding POMC, under the control of a doxycycline-responsive promoter in association with plasmid encoding, for tetracycline regulators of the expression of genes. A single injection of equimolar amounts of the two plasmids followed by five square-wave electric pulses of 200 V/75 ms was found to produce stable high levels of CSF betaendorphin without doxycycline injection. In the presence of doxycycline, the beta-endorphin level decreased in a dose-related manner. Saitoh et al 27 reported that polymer-encapsulated mouse neuroblastoma cells that are capable of secreting beta-endorphin might reduce pain sensitivity in rats more than 1 month after capsule implantation into the CSF-filled subarachnoid space of the spinal cord. In a later study, Saitoh et al 28 demonstrated the feasibility of a regulated release of ACTH from POMC-Neuro2A cells via the administration of doxycycline. The concept of a regulated release of beta-endorphin is appealing. The approach provides more pertinent adjustment for the treatment of pain. Regulation can also be achieved with dexamethasone. 29 However, long-term and regulated release of beta-endorphin presently requires the use of exogenous cell lines, which presents some problems even when the cells are encapsulated. Finegold et al 18 delivered beta-endorphin cDNA into the spinal space using an adenoviral vector, and successfully transfected the cells of the pia mater to secrete beta-endorphin for 2 weeks, thereby establishing a paradigm for paracrine therapy for chronic pain. To avoid possible side effects associated with viral vectors, we used a nonviral technique to deliver the plasmid encoding beta-endorphin to the central nervous system.
Electroporation is a gene delivery strategy that combines 'naked' DNA injection with pulsed electric field treatment. 30 This nonviral approach provides remarkably efficient transgenic expression, and in the case of application in muscle tissue, the expression can be long lived. The process allows efficient cytoplasmic uptake of large and highly charged polynucleotide molecules that normally require either specialized (and often toxic) delivery cofactors or, in the case of naked DNA transfection, are taken up relatively inefficiently. 31 Figure 6 (a) Time course for concentrations of beta-endorphin in spinal microdialysate samples in animals that received the pTRE-POMC/pTel-off electroporation. Note peak concentrations at days 4-6 after electroporation. (b) Decrement of beta-endorphin levels in the spinal microdialysate of the rats that received doxycycline injection 6 days after CCI lesion. In animals that received intrathecal pTRE-POMC/pTel-off electroporation, intraperitoneal injection of doxycycline at doses 0, 0.001, and 0.1 mg/kg did not affect beta-endorphin levels, but injection of doxycycline at 1 mg/kg reduced beta-endorphin level values 12, 24, and 36 h after injection. Slight but significant decrement of beta-endorphin level was noted 24 h after 0.1 mg/kg doxycycline injection. Values are expressed as means7s.e.m. *indicates statistically significant difference from values of saline injected rats (Po0.05).
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Furthermore, multiple genes can also be examined simultaneously by coelectroporation of mixed expression vectors, 32 and blocking gene function or expression is also possible using dominant negative molecules. 33 These analyses can be performed in normal or mutant animals, which could potentially enhance approaches to studying normal and mutant cell behaviors and phenotypes.
We have shown in our previous study that the spinal cord can be used as a factory in vivo to produce and secrete the analgesic molecule beta-endorphin. 17, 19 The cellular distribution of the transferred gene was noted in the meningeal cells, the pia mater, and to a less extent, the dorsal horn. Despite short-term expression, this method of gene transfer to non-neuronal cells to affect neuronal function is a highly accessible paradigm for gene therapy of spinal cord related disease. The nonneuronal meningeal target provides a simple and safe route of administration and allows manipulation of neuronal function. The neuronal target provides direct regulation of pain-related signal transduction in the dorsal horn. The spatial distribution of beta-endorphins provides segmental gene transfer for specific targeting to modulate the excitability of the primary sensory-afferent branching. These observations offer an interesting therapeutic perspective since intrathecal tissue is easy to access, and it can be, moreover, repeatedly electrotransferred with the same therapeutic plasmid. 34 Since gene electrotransfer drives a continuous delivery of betaendorphin in the CSF, it is important to consider the overdose toxicity that might result as an important safety issue. The possibility of adjusting CSF levels of the factor according to the need of each patient is thus critical. Coupling electrically mediated plasmid delivery with a tetracycline-inducible Tet-off system fulfills this prerequisite by achieving tight control of CSF beta-endorphin. This is illustrated by the nearly undetectable transgene expression after 1 mg/kg doxycycline injection. These results demonstrate that the system can accentuate the safety issue concerning side effects caused by spinal POMC electroporation.
In conclusion, we have shown that intrathecal pTRE2-POMC/pTel-off electroporation alleviates CCI-induced limb pain and is controllable by intraperitoneal doxycycline administration. Moreover, successful delivery of these plasmids to the spinal cord offers the potential of long-term gene therapy mediated by simple intrathecal injection, avoiding the need for cell culture, transplantation, immunosuppression or toxic small molecule transcriptional regulators. Although physiological minute-to-minute beta-endorphin regulation may not be attainable, this approach may suffice as a sole or complementary treatment for chronic pain.
Materials and methods

Experimental design
We divided our experiment into three parts. In the first set, we studied the regulatory effects of doxycycline on the beta-endorphin secretion in cultured spinal neuronal cells transfected with pTRE2-POMC/pTel-off plasmid (Clontech, Palo Alto, CA, USA) in vitro. Cultured spinal neuronal cells received pTRE2-POMC/pTel-off plasmid DNA using a single brief electric pulse of 150 V with a duration of 20 ms. Cells were cultured with medium containing various concentrations of doxycycline (10 À3 -1 mg/ml). Medium was collected every 24 h, and betaendorphin production in the medium was measured using RIA.
In the second set, we studied the antihyperalgesic effect of intrathecal pTRE2-POMC/pTel-off electroporation in CCI rats. CCI rats (n ¼ 6 per group) were randomly assigned to one of seven treatment groups. Depending upon group designation, the animals received either electroporation with pTRE2-POMC/pTeloff, pTRE2-POMC/pTel-off or vehicle, or intrathecal pTRE2-POMC/pTel-off or vehicle only. Animals received intrathecal electroporation immediately after sciaticnerve injury. Thermal and mechanical withdrawal latencies were measured before CCI, and then on evennumbered days, up to and including the 14th day, to assess and compare the therapeutic effects of intrathecal electroporation. Another two groups were assigned to receive intrathecal pTRE2-POMC/pTel-off or vehicle electroporation with intraperitoneal naloxone (1 mg/ kg) at day 6 to determine whether the analgesic effect after transplantation was induced by beta-endorphin. Pain sensitivity was measured by thermal and mechanical withdrawal latency every 30 min until 90 min after the injection.
In the third set of experiments, we studied the effect of intraperitoneal doxycycline administration in the regulation of beta-endorphin expression using thermal and mechanical latencies assessment and intrathecal microdialysis. CCI rats (n ¼ 6 per group) that had received intrathecal pTRE2-POMC/pTel-off (100 mg) electroporation were randomly assigned to one of the five groups to receive vehicle, doxycycline 0.01, 0.1, or 1 mg/kg at day 6. The fifth group that received vehicle electroporation only served as a second control. Thermal and mechanical withdrawal latencies were measured every 12 h for 36 h, then every 24 h for 1 day. The dialysate from intrathecal microdialysis was assessed for betaendorphin by the RIA method.
Human pTRE2-POMC cDNA expression plasmid construction
Total RNA from the human pituitary gland was obtained using TriZol Reagent (Gibco, Grand Island, NY, USA). cDNA was synthesized by reverse transcriptase using oligo-dT as the primer (BcaBEST RNA PCR kit; TaKaRa Biomedicals, Otsu, Japan). The POMC gene was then amplified by PCR using specific upstream and downstream oligonucleotides. The upstream oligonucleotide was 5 0 -CAG ggT aCC TGG AAG ATG CCG AGA TC-3 0 , and the downstream analog was 5 0 -CCT GGG taC CGCTGT GCC CTC ACT CG-3 0 , where lowercase letters indicate changes to incorporate KpnI cutting sites (underlined). The PCR product contained the full-length coding region of the POMC gene, with an expected length of 854 bp. After cloning into a pUC18 vector white colonies (LacZ mutation) were selected, and plasmid DNA was purified using the Mini Plasmid DNA Preparation Kit (Qiagen, Valencia, CA, USA), digested using KpnI, and electrophoresed on an agarose gel. Plasmids containing the correct insert size were further verified by DNA sequencing. The plasmid insert containing the correctly orientated full-length POMC gene was Transfer of pTRE2-POMC/pTel-off into cultured spinal neuronal cells through in situ electroporation
Spinal neuronal cells were isolated from rat lumbar spinal cords using the Papain Dissociation System (Worthington Biochemical Corp., Freehold, NJ, USA) as described previously. 35 Cells were plated in a six-well plate at 10 6 cells/ml in 2 ml complete medium per well, and the cells obtained 75% confluence on the day of electric pulse treatment. Cells were washed twice with 1 ml Neurobasal medium (Gibco, Grand Island, NY, USA) and incubated using 0.6 ml ViaSpan (DuPont Pharmaceutica, mixed with 20 mg pTRE2-POMC/pTeloff for 15 min at room temperature. The cells were then exposed to a single brief electric pulse, delivered from a BTX 35 mm Petri Pulser (BTX; Electrogenetics, Islip, NY, USA) of 250 V for 40 ms at room temperature. At 5 min after pulsing, 2.4 ml prewarmed complete medium was added. After 3-h incubation, the medium was changed once to ensure good cell survival. 33 General preparation/electrode construction After receiving permission from the Institute Review Board of the Chang Gung University, a total of 72 male Sprague-Dawley rats (National Science Council, Taipei, Taiwan) weighing 300-350 g were studied in accordance with the guidelines for pain research. An electrodemicrodialysis catheter was implanted intrathecally using a previously described technique. 36 Briefly, an electrodemicrodialysis catheter was constructed by passing a platinum wire (0.066 mm) into the intrathecal catheter of a three-lumen microdialysis probe (9 cm long; Marsala Co., San Diego, CA, USA) protruding 5 mm and covered by microdialysis membrane. While the rats were under 2.5% isoflurane anesthesia, the probes were implanted into the rats' intrathecal lumbar (L3-4) space through a cisternal incision. The animals were allowed to recover for 2 days. Gene transfer was accomplished via direct intrathecal injection of 100 mg of plasmid as in our previous experiment. The electrode was contacted with a negative electrode clamp through the sheath. A positive electrode was placed on the animal's tail, and electric pulses were applied using a pulse generator (BTX ECM830; Genetronics, San Diego, CA, USA).
CCI of sciatic nerves
Bennett's neuropathic model was used as the basis for generation of neuropathic pain. The right sciatic nerve was exposed under isoflurane anesthesia. Proximal to the sciatic trifurcation, about 7 mm of the nerve was freed of adhering tissue and four ligatures (5-0 chromic gut) were loosely tied around it at 0.5-1.0 mm intervals.
The incision was closed in layers and prophylactic penicillin (50 mg/kg) was administered intramuscularly, followed by subcutaneous injection of 5 ml of 5% glucose solution to prevent dehydration. Exposing the left sciatic nerve without performing ligation served as sham surgery. Animals were maintained under standard colony conditions with food and water available ad libitum.
Behavioral assessment of thermal and mechanical stimulation
The thermal nociceptive threshold was measured before and after induction of the nerve injury, or after intrathecal electroporation, using a technique somewhat modified from the one originally described by Hargreaves et al 37 in 1988. The animal was placed on a glass plate (maintained at 301C) for 5-10 min for adaptation. Latency between the application of a focused light beam and the hind-paw-withdrawal response was measured to the nearest 0.1 s, with a cutoff time in the absence of response after 20 s.
Foot withdrawal threshold in response to a mechanical stimulus was determined using a series of von Frey filaments (Stoelting, Wood Dale, IL, USA), ranging from 0.23 to 59.0 g. Animals were placed in a plastic cage with a metal mesh floor, allowing them to move freely. They were allowed to acclimatize to this environment before the experiment. The filaments were presented to the midplantar surface. Values for withdrawal latency were then determined at daily intervals for up to 14 days.
Assessment of CSF beta-endorphin levels using intrathecal microdialysis
The recovery rate of the microdialysis for each catheter was measured before each experiment. The in vitro betaendorphin recovery (at flow rate of 3 ml/min), as determined by placing in artificial CSF (ACSF) (151.1 mM Na þ , 2.6 mM K þ , 0. , and 3.5 mM dextrose) containing beta-endorphin, was 1872.1%.
For every dialysis, animals were reanesthetized with 2.5% isoflurane, and the dialysis catheters were perfused with ACSF at a rate of 3 ml/min. The ACSF was bubbled with 95% oxygen/5% CO 2 before each experiment to adjust the final pH to 7.2. All experimental manipulations were preceded by a 30-min washout period and then followed by two control sample (20 min each) collections.
After the baseline samples were collected, animals were allowed to recover, and dialysate samples were collected every 2 days after intrathecal electroporation. A volume of 50 ml of dialysate was assayed by the RIA kit (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). This commercially available kit has a detection threshold of 1.4 pmol/l.
Data analysis
All data were expressed as the mean7s.e.m. Statistical evaluation of the thermal latency in the thermal test and the hind-paw-withdrawal threshold in the von Frey hair test was performed in each group with one-way repeated measures analysis of variance. Statistical comparisons between groups for the thermal test, the von Frey hair test, and beta-endorphin levels were performed by oneway factorial analysis of variance followed by a multiple comparison test (the Bonferroni test). A P-value of o0.05 was considered statistically significant. 
